First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.

Cancers (Basel) · 2023 · PMC10137202 · PMID 37190312

Europe PMC DOI

hedged sentence

0.0725

closest p · 1.4× alpha

0.0725

boldest claim

The sentences

trending towards significancep = 0.0725so close (0.05 < p ≤ 0.1)

An improvement in OS was also noted to be trending towards significance with the use of Osimertinib compared to erlotinib/gefitinib (not reached vs. 20.9 months, p = 0.0725) [ 27 ].

also in 128 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.